BioPharmSignal logoBioPharmSignal

Biotech News

Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

Personalis (PSNL)PersonalisEarnings

FREMONT, Calif. --(BUSINESS WIRE)--Feb. 12, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026.

Related news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

GERNGeron2026-07-22 11:00 EST

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

View all latest news

Personalis

Precision-Oncology Genomics Personalis develops genomic tests for cancer detection, monitoring and therapy development. Its platform uses highly sensitive sequencing and tumor-informed analysis to identify minimal residual disease. NeXT Personal NeXT Personal is a personalized circulating-tumor-DNA test designed to detect and track...

Recent company news

PSNLPersonalis2026-08-04 20:01 EST

Personalis Reports Second Quarter Results and Recent Highlights

PSNLPersonalis2026-07-20 12:30 EST

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

PSNLPersonalis2026-07-14 10:00 EST

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

PSNLPersonalis2026-06-09 10:00 EST

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

PSNLPersonalis2026-06-02 10:00 EST

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Stock data

Close
18.38 USD
Market cap
1.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States